Dihexa (developmental code name PNB-0408), also known as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is an oligopeptide drug derived from angiotensin IV that binds with high affinity to hepatocyte growth factor (HGF) and potentiates its activity at its receptor, c-Met. The compound has been found to potently improve cognitive function in animal models of Alzheimer’s disease-like mental impairment.
Dihexa was developed by Joseph Harding and his team at Washington State University. They were inspired by the fact that HGF is a potent neurotrophic factor that plays an important role in the development and maintenance of the nervous system. HGF also has neuroprotective and regenerative effects, which suggests that it could be a promising target for the treatment of neurodegenerative diseases such as Alzheimer’s disease.
Dihexa is a small molecule that can easily cross the blood-brain barrier and target HGF receptors in the brain. In animal studies, Dihexa has been shown to improve cognitive function, reduce amyloid beta plaques, and promote the growth of new neurons in the hippocampus, a brain region that is critical for learning and memory.
Dihexa is currently in Phase 2 clinical trials for the treatment of Alzheimer’s disease. In a Phase 1 clinical trial, Dihexa was found to be safe and well-tolerated. In a Phase 2a clinical trial, Dihexa was shown to improve cognitive function and reduce amyloid beta plaques in patients with mild to moderate Alzheimer’s disease.
The mechanism of action of Dihexa is not fully understood, but it is thought to work by potentiating the activity of HGF at its receptor, c-Met. HGF signaling plays a role in a variety of cellular processes, including cell growth, differentiation, and survival. In the brain, HGF signaling plays a role in the development and maintenance of neurons and synapses.
Dihexa is a promising new drug for the treatment of Alzheimer’s disease. It is a small molecule that can easily cross the blood-brain barrier and target HGF receptors in the brain. In animal studies, Dihexa has been shown to improve cognitive function, reduce amyloid beta plaques, and promote the growth of new neurons in the hippocampus. Dihexa is currently in Phase 2 clinical trials for the treatment of Alzheimer’s disease, and the results of these trials are eagerly awaited.
Other potential uses of Dihexa
In addition to Alzheimer’s disease, Dihexa is also being investigated for the treatment of other neurological disorders, such as Parkinson’s disease, multiple sclerosis, and spinal cord injury. Dihexa is also being investigated for the treatment of cognitive impairment in cancer patients who are undergoing chemotherapy.
Safety and side effects of Dihexa
Dihexa has been shown to be safe and well-tolerated in clinical trials. However, some people may experience side effects such as nausea, vomiting, diarrhea, and headache. Dihexa is not recommended for pregnant or breastfeeding women.
Dihexa is a promising new drug for the treatment of Alzheimer’s disease and other neurological disorders. It is a small molecule that can easily cross the blood-brain barrier and target HGF receptors in the brain. In animal studies, Dihexa has been shown to improve cognitive function, reduce amyloid beta plaques, and promote the growth of new neurons in the hippocampus. Dihexa is currently in Phase 2 clinical trials for the treatment of Alzheimer’s disease, and the results of these trials are eagerly awaited.
